Loading
NASDAQHealthcareBiotechnology
Latest quote
$0.8426
+$0.0206 · +2.51%
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Previous close
$0.8426
+$0.0206 · +2.51%
Regular session · ET · Market data may be delayed.
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Day range
Current $0.8426
52-week range
Current $0.8426
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
68
Undervalued
Sentiment
41
Mixed
Risk
68
High Risk
Momentum
19
Strong Down
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Rani Therapeutics Holdings, Inc. functions as a clinical-stage biopharmaceutical enterprise focused on revolutionizing the delivery of biologic therapies through oral administration. Its flagship innovation, the RaniPill capsule, aims to supplant conventional subcutaneous or intravenous injections of biologics with a more convenient oral dosing method. The company maintains a comprehensive portfolio of investigational treatments. Among these is RT-101, an octreotide, which has progressed beyond Phase I clinical trials for the management of neuroendocrine tumors and acromegaly. Another promising candidate is RT-105, an anti-TNF-alpha antibody designed to address psoriatic arthritis. Additionally, RT-102, a parathyroid hormone for osteoporosis, is currently advancing through preclinical studies. Other therapies under development include RT-109, a human growth hormone for treating growth hormone deficiency; RT-110, a parathyroid hormone aimed at hypoparathyroidism; and RT-106, a basal insulin formulated for type 2 diabetes. Established in 2012, the company's corporate base is located in San Jose, California.
Day range
Current $0.8426
52-week range
Current $0.8426
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 1.63M USD | 1.03M USD | — | — | 2.72M USD |
| Cost of goods sold | 900K USD | — | 822K USD | — | — |
| Gross profit | 733K USD | 1.03M USD | −822K USD | — | 2.72M USD |
| Research and development | 20.21M USD | 26.68M USD | 39.62M USD | 36.61M USD | 26.48M USD |
| Selling, general, and administrative | 19.74M USD | 23.95M USD | 26.48M USD | 26.84M USD | 27.83M USD |
| Operating expenses | 39.04M USD | 54.34M USD | 65.28M USD | 63.45M USD | 54.32M USD |
| Interest income | 827K USD | 1.76M USD | 3.3M USD | 1.25M USD | 89K USD |
| Interest expense | 2.89M USD | 5.03M USD | 5.09M USD | 1.07M USD | 466K USD |
| Depreciation and amortization | 900K USD | 1.03M USD | 822K USD | 548K USD | 497K USD |
| Operating income | −38.31M USD | −53.31M USD | −66.1M USD | −63.45M USD | −51.6M USD |
| Net income | −29.67M USD | −30.02M USD | −33.97M USD | −30.59M USD | −8.33M USD |
Company facts updated Sep 12, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$15.67
1759.72% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI2.82M0.00%2.3T USD0.03%$376.31+0.82%
Vanguard Extended Market ETFVXF646.29K0.00%93.7B USD0.05%$237.76+0.68%
Invesco Nasdaq Biotechnology ETFIBBQ5.86K0.01%95.7M USD0.19%$34.472+0.09%
ProShares Ultra Nasdaq BiotechnologyBIB3.18K0.00%95.38M USD1.19%$109.77+0.16%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
